Tourmaline Bio, Inc. (TRML) Stock Analysis & Investment Frameworks
Tourmaline Bio, Inc. (TRML) stock analysis on Invetso. Review Tourmaline Bio, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Tourmaline Bio, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Tourmaline Bio, Inc. Key Financial Metrics
- Market Cap: $1.23B
- Revenue: $N/A
- ROE: -28.99%
- ROIC: -29.88%
- Dividend Yield: N/A
About Tourmaline Bio, Inc.
Tourmaline Bio, Inc. is a clinical-stage biotechnology firm committed to advancing therapies for individuals suffering from debilitating immune disorders. The company's development pipeline focuses on conditions such as Atherosclerotic Cardiovascular Disease (ASCVD) and Thyroid Eye Disease (TED). Established in 2021, this enterprise is headquartered in New York, New York.
Tourmaline Bio, Inc. Investment Frameworks
Invetso analyzes Tourmaline Bio, Inc. (TRML) across the following frameworks:
- Tourmaline Bio, Inc. 10Y Growth Potential
- Tourmaline Bio, Inc. Scenario Analysis
- Tourmaline Bio, Inc. Risks & Opportunities
- Tourmaline Bio, Inc. Economic Moat
- Tourmaline Bio, Inc. Business Model
- Tourmaline Bio, Inc. Management
- Tourmaline Bio, Inc. SWOT Analysis
- Tourmaline Bio, Inc. Porter's 5 Forces
- Tourmaline Bio, Inc. PESTLE Analysis
- Tourmaline Bio, Inc. ESG Analysis